PRLD - Prelude Therapeutics EPS beats by $0.13 March, 16 2021 09:31 AM Prelude Therapeutics Incorporated Prelude Therapeutics (PRLD): Q4 GAAP EPS of -$0.45 beats by $0.13.Cash and cash equivalents of $218.3M as of December 31, 2020Press Release For further details see: Prelude Therapeutics EPS beats by $0.13